KDM1A and osteosarcoma: Owing to its high expression in several solid malignancies including breast [59–61], colorectal [62, 63], lung [62, 64], ovarian cancer [65], undifferentiated neuroblastoma [66], prostate carcinoma [67, 68], urothelial carcinoma [62], and sarcomas (Ewing, chondrosarcoma, osteosarcoma, rhabdomyosarcoma, and synovial) [69, 70], specific small molecule inhibitors of LSD1 have been aggressively pursued as potential therapeutics.